Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.52 |
| ▸ | ABAT | P80404 | 2/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.40 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | OAT | P04181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295283 | 0.97 | — | — | |
| SCHEMBL4287590 | 0.97 | — | — | |
| SCHEMBL761864 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL25299022 | 0.94 | — | — | |
| SCHEMBL2890441 | 0.94 | GABRR1 (0.52) | GABRR1ABATSLC6A12SLC6A11SLC6A13 | |
| Hydrochloric Acid SCHEMBL16763788 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL364236 | 0.94 | — | — | |
| SCHEMBL8204743 | 0.84 | CYP2C19 (0.50) | GABRR1ABATSLC6A11CYP2C19CYP1A2 | |
| SCHEMBL6542917 | 0.84 | CYP2C19 (0.50) | GABRR1ABATSLC6A11CYP2C19CYP1A2 | |
| SCHEMBL375124 | 0.84 | CYP2C19 (0.50) | GABRR1ABATSLC6A11CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169759-B1 | Tetrapeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2007-01-30 | — | — | US | claimed |
| US-20050182138-A1 | Dipeptide inhibitors of beta-secretase | ELAN PHARMACEUTICALS, INC. | 2005-08-18 | — | — | US | claimed |
| US-6864240-B1 | Dipeptide inhibitors of β-secretase | ELAN PHARMACEUTICALS, INC. (US) | 2005-03-08 | — | — | US | claimed |
| EP-1192177-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| WO-2000077030-A1 | STATINE-DERIVED TETRAPEPTIDE INHIBITORS OF BETA-SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | claimed |
| EP-4692949-A1 | POSITIVELY CHARGEABLE TONER FOR ELECTROSTATIC CHARGE IMAGE DEVELOPMENT, TONER SET, AND IMAGE FORMING METHOD | Zeon Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024202238-A1 | POSITIVELY CHARGEABLE TONER FOR ELECTROSTATIC CHARGE IMAGE DEVELOPMENT, TONER SET, AND IMAGE FORMING METHOD | 日本ゼオン株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-11753500-B2 | Epoxy resin solution | UNITIKA LTD. (JP) | 2023-09-12 | — | — | US | disclosed |
| CN-113396173-B | Epoxy resin solution | 尤尼吉可株式会社 | 2023-09-12 | — | — | CN | disclosed |
| US-20220106435-A1 | EPOXY RESIN SOLUTION | UNITIKA LTD. (JP) | 2022-04-07 | — | — | US | disclosed |
| EP-3919541-A1 | EPOXY RESIN SOLUTION | Unitika Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| CN-113396173-A | Epoxy resin solution | 尤尼吉可株式会社 | 2021-09-14 | — | — | CN | disclosed |
| US-6992081-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-6737420-B2 | A SUBSTITUTED HYDROXYETHYLENE COMPOUND USEFUL FOR TREATING ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, DOWN'S SYNDROME, HEREDIATARY CEREBRAL HEMMORRHAGE WITH AMYLOIDOSIS, DEGENERATIVE DEMENTIA | ELAN PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| EP-1265849-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001070672-A2 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | GABRR1 1469/4885ABAT 1110/4885SLC6A12 3870/4885 |
| US-20020019403-A1 | Methods to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | GABRR1 804/4885ABAT 1009/4885SLC6A12 3025/4885 |
| US-20030013881-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BACE1 | GABRR1 1308/4885ABAT 753/4885SLC6A12 3259/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | GABRR1 1469/4885ABAT 1110/4885SLC6A12 3870/4885 |
| US-20050182138-A1 | Dipeptide inhibitors of beta-secretase | BACE1, APP, BACE2 | GABRR1 1441/4885ABAT 476/4885SLC6A12 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.